Search Page

1

Cite

Share

Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis.

Bushey RT, Gottlin EB, Campa MJ, Patz EF Jr. Bushey RT, et al. PLoS One. 2021 Jun 16;16(6):e0252577. doi: 10.1371/journal.pone.0252577. eCollection 2021. PLoS One. 2021. PMID: 34133431 Free PMC article.

Cite

Share

2

Cite

Share

Genetic Variants of CLPP and M1AP Are Associated With Risk of Non-Small Cell Lung Cancer.

Li X, Zou Y, Li T, Wong TKF, Bushey RT, Campa MJ, Gottlin EB, Liu H, Wei Q, Rodrigo A, Patz EF Jr. Li X, et al. Among authors: bushey rt. Front Oncol. 2021 Sep 15;11:709829. doi: 10.3389/fonc.2021.709829. eCollection 2021. Front Oncol. 2021. PMID: 34604049 Free PMC article.

Cite

Share

3

Cite

Share

A Therapeutic Antibody for Cancer, Derived from Single Human B Cells.

Bushey RT, Moody MA, Nicely NL, Haynes BF, Alam SM, Keir ST, Bentley RC, Roy Choudhury K, Gottlin EB, Campa MJ, Liao HX, Patz EF Jr. Bushey RT, et al. Cell Rep. 2016 May 17;15(7):1505-1513. doi: 10.1016/j.celrep.2016.04.038. Epub 2016 May 5. Cell Rep. 2016. PMID: 27160908 Free PMC article.

Cite

Share

4

Cite

Share

Prognostic significance of a complement factor H autoantibody in early stage NSCLC.

Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF Jr. Gottlin EB, et al. Among authors: bushey rt. Cancer Biomark. 2022;34(3):385-392. doi: 10.3233/CBM-210355. Cancer Biomark. 2022. PMID: 35068447

Cite

Share

5

Cite

Share

Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Dluzen DF, Sun D, Salzberg AC, Jones N, Bushey RT, Robertson GP, Lazarus P. Dluzen DF, et al. Among authors: bushey rt. J Pharmacol Exp Ther. 2014 Mar;348(3):465-77. doi: 10.1124/jpet.113.210658. Epub 2014 Jan 7. J Pharmacol Exp Ther. 2014. PMID: 24399855 Free PMC article.

Cite

Share

6

Cite

Share

Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism.

Bushey RT, Dluzen DF, Lazarus P. Bushey RT, et al. Drug Metab Dispos. 2013 Jan;41(1):170-9. doi: 10.1124/dmd.112.049171. Epub 2012 Oct 18. Drug Metab Dispos. 2013. PMID: 23086198 Free PMC article.

Cite

Share

7

Cite

Share

Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis.

Bushey RT, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P. Bushey RT, et al. Pharmacogenet Genomics. 2011 Feb;21(2):55-65. doi: 10.1097/FPC.0b013e328341db05. Pharmacogenet Genomics. 2011. PMID: 21164388 Free PMC article.

Cite

Share

8

Cite

Share

Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy.

Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr. Campa MJ, et al. Among authors: bushey rt. Cancer Immunol Res. 2015 Dec;3(12):1325-32. doi: 10.1158/2326-6066.CIR-15-0122. Epub 2015 Jul 27. Cancer Immunol Res. 2015. PMID: 26216416

Cite

Share

9

Cite

Share

Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility.

Bushey RT, Lazarus P. Bushey RT, et al. J Pharmacol Exp Ther. 2012 Dec;343(3):712-24. doi: 10.1124/jpet.112.198770. Epub 2012 Sep 13. J Pharmacol Exp Ther. 2012. PMID: 22984225 Free PMC article.

Cite

Share

10

Cite

Share

Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody.

Winkler MT, Bushey RT, Gottlin EB, Campa MJ, Guadalupe ES, Volkheimer AD, Weinberg JB, Patz EF Jr. Winkler MT, et al. Among authors: bushey rt. PLoS One. 2017 Jun 28;12(6):e0179841. doi: 10.1371/journal.pone.0179841. eCollection 2017. PLoS One. 2017. PMID: 28658265 Free PMC article.

Cite

Share